Wedbush Upgrades Zentalis Pharmaceuticals to Outperform
The upgrade and substantial gap between the target and posted price are bullish, but the move already underway and the lack of supporting rationale warrant caution.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The upgrade and substantial gap between the target and posted price are bullish, but the move already underway and the lack of supporting rationale warrant caution.
What happened, with direct paths to the underlying reporting
Wedbush upgraded ZNTL to Outperform and set a $6 target versus the posted price of $1.74. Shares had already risen 12.93% since the signal.
Target: $6
Posted price: $1.74
Analyst firm: Wedbush
Analyst: Robert Driscoll
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.